Infection
Year in review
Tuberculosis: short-course chemotherapy
and Ceremony for the ERS Research Award: Innovation in Non-Tuberculous Mycobacteria Science and Medicine
Aims : To present the evidence base for improving tuberculosis treatment with current and new drugs, discuss the evidence that suggests a need for shorter-course treatments for tuberculosis, the possible reasons for the problems that may be faced in shortening tuberculosis treatment with reference to the basic science of tuberculosis and present recommendations for future trials.
08:30
Ceremony for the ERS Research Award: Innovation in Non-Tuberculous Mycobacteria Science and Medicine
G. Sotgiu(Sassari, Italy)
COI
R. Floto(Cambridge (Cambridgeshire), United Kingdom)
COI
1
1707
08:40
The role of moxifloxacin in treating tuberculosis
S. Gillespie(St. Andrews, United Kingdom)
COI
2
1708
09:07
High-dose rifampicin and rifapentine in tuberculosis treatment
A. Jindani(London, United Kingdom)
COI
3
1709
09:34
Four-month regimens: are they feasible?
C. Lienhardt(Genève 27, Switzerland)
COI
4
1710
10:01
Short-course treatment for multidrug-resistant tuberculosis: STREAM trials
S. Meredith(London, United Kingdom)
COI
5
1711
. . .
